



Source

FITC-Labeled Anti-Rituximab Antibodies, Mouse IgG1 (RIB-FY35c) are expressed from human 293 cells (HEK293).

Isotype

Mouse IgG1/kappa

Specificity

Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.

Conjugate

FITC

Excitation source: 488 nm spectral line, argon-ion laser

Excitation Wavelength: 488 nm

Emission Wavelength: 535 nm

Labeling

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

Protein Ratio

The FITC to protein molar ratio is 1-3.

Application

ELISA

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μ m filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.

SDS-PAGE



FITC-Labeled Anti-Rituximab Antibody, Mouse IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity


Discounts, Gifts,
and more!






of the protein is greater than 95%.

Bioactivity-Elisa



Immobilized Rituximab at 2 µg/mL (100 µL/well) can bind FITC-Labeled Anti-Rituximab Antibody, Mouse IgG1 (Cat. No. RIB-FY35c) with a linear range of 0.01-0.3 µg/mL (QC tested).

Bioactivity-FACS



2e5 of Anti-CD20 (Rituximab) CAR-293 cells were stained with 100 µL of 3 µg/mL of FITC-Labeled Anti-Rituximab Antibody, Mouse IgG1 (Cat. No. RIB-FY35c) and isotype control antibody respectively. FITC signal was used to evaluate the binding activity (QC tested).

Background

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids

Clinical and Translational Updates

Discounts, Gifts,
and more!

